

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 14085

Title: Phase II study of a combination chemotherapy with weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Reviewer code: 00052396

Science editor: Jing Yu

Date sent for review: 2014-09-19 14:23

Date reviewed: 2014-10-25 05:36

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This manuscript by Lee et al is a descriptive study by nature. It clearly shows that combination chemotherapy with docetaxel and gemcitabine is an effective treatment for previously treated metastatic esophageal squamous cell carcinoma. There are several comments as follows: 1. Reference 5 is misquoted on page 5 (1st paragraph). It should be replaced by a reference on esophageal squamous cell carcinoma. 2. The dose of Docetaxel (35mg/m²) needs to be justified. 3. "The most common first-line chemotherapy regimen was 5-FU plus cisplatin (76%) followed by capecitabine plus cisplatin or paclitaxel (24%)" (1st paragraph, page 10). This is contradictory to the criteria of inclusion, which include "prior exposure to taxanes or gemcitabine" (1st paragraph, page 7). 4. In Discussion section, the authors need to quote historical data to show the advantage of docetaxel/gemcitabine as compared with other second-line regimen or palliative therapy without chemotherapy in terms of overall survival etc. 5. Two previous studies may be quoted and compared with this study: Med Oncol 2007;24(4):407-12. OncoTargets Therapy 2014;7:1875-81.



ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 14085

Title: Phase II study of a combination chemotherapy with weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Reviewer code: 02979093

Science editor: Jing Yu

Date sent for review: 2014-09-19 14:23

Date reviewed: 2014-10-26 12:06

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Typographical errors: Page 5 2nd Paragraph line 3- should be in the salvage setting in particular, the toxicity... Page 5 2nd Para line 10 - has not have Page 6 2nd Para line 2- As such, a weekly schedule... Page 10 Para 1 last line- should be but did not benefit (instead of was not benefited) Page 12 Para 3 line 1- should be "in the second-line"... Suggest referencing Recist1.1 in methods section and not putting all the specific details. Ie clinical tumor response was assessed according to RECIST 1.1 [insert reference] In discussion setting- cannot conclude low incidence of severe hematologic toxicities with 39% G3 neutropenia. You could conclude that it had an acceptable or tolerable toxicity profile. Suggest some of the discussion section regarding historical data be moved to the introduction section and remove some of the repetition. Some of the discussion should focus on the activity reported in the current setting in comparison to other second line regimens and focus on the advantages of the current schedule over alternative treatment options. There needs to be some discussion regarding the limitations of the current study. There should be some discussion regarding the relative merits of fixed dose rate and standard gemcitabine dosing, particularly with regards to potential disadvantages of the fixed dose rate regimen (specifically myelosuppression).



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 14085

Title: Phase II study of a combination chemotherapy with weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Reviewer code: 02508408

Science editor: Jing Yu

Date sent for review: 2014-09-19 14:23

Date reviewed: 2014-11-02 01:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The authors performed a phase II study to determine the efficacy and safety of combination chemotherapy with weekly docetaxel and gemcitabine in previously treated patients with metastatic esophageal squamous cell carcinoma. In general, the clinical study was well-designed and well-performed. The results showed that this salvage combination regimen has potential benefit for patients with previously treated metastatic esophageal SCC. The manuscript is clearly written and the findings clinically relevant.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 14085

Title: Phase II study of a combination chemotherapy with weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Reviewer code: 02976687

Science editor: Jing Yu

Date sent for review: 2014-09-19 14:23

Date reviewed: 2014-10-01 10:07

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

A good quantity of work is presented and some interesting results were observed. Any clinical trial should be registered. Please submit related registration information of ethics.